Cost-effectiveness of ensuring hepatitis B protection for previously vaccinated healthcare personnel

Infection Control and Hospital Epidemiology

Volumn 35, Issue 7, 2014, Pages 845-854

  Hoerger, Thomas J ^a   Bradley, Christina ^a   Schillie, Sarah F ^b   Reilly, Meredith ^b   Murphy, Trudy V ^b  

^a RTI INTERNATIONAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ARTICLE; CONTROL STRATEGY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL MANAGEMENT; HEALTH CARE SYSTEM; HEPATITIS B; HUMAN; INFECTION RISK; LONG TERM CARE; POST EXPOSURE PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STUDENT; VACCINATION; BLOOD; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE TRANSMISSION; ECONOMICS; HEALTH CARE PERSONNEL; INFECTION CONTROL; PRE-EXPOSURE PROPHYLAXIS; PREVENTION AND CONTROL;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH PERSONNEL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; INFECTION CONTROL; INFECTIOUS DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; PRE-EXPOSURE PROPHYLAXIS; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 84902975012     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/676865     Document Type: Article

References (39)

1. New York Center for Health Workforce Studies. The United States Health Workforce Profile: October 2006. Rensselaer, NY: New York Center for Health Workforce Studies, 2006. http://bhpr.hrsa.gov/healthworkforce/reports/ushealthwork2006.pdf.
2. Centers for Disease Control and Prevention. Updated U.S. public health service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 2001; 50(RR-11):1-52
3. Centers for Disease Control and Prevention. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWRMorb Mortal Wkly Rep 2013;62(RR-10);1-19
4. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP): part II: immunization of adults. MMWRMorb Mortal Wkly Rep 2006; 55(RR-16):1-33
5. Lu P-J, Byrd KK, Murphy TV, Weinbaum C. Hepatitis B vaccination coverage among high-risk adults 18-49 years, U.S. 2009. Vaccine 2011;29:7049-7057
6. Beltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev 2000;13(3):385-407
7. Centers for Disease Control and Prevention (CDC). Viral Hepatitis Surveillance-United States, 2010. Atlanta: CDC, 2012. http://www.cdc.gov/hepatitis/Statistics/2010Surveillance/index.htm.
8. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009;200:1390-1396
9. Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011;18(5):369-375
10. Zhu CL, Liu P, Chen T, et al. Presence of immune memory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine 2011;29(44):7835-7841
11. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40(RR-13):1-25
12. Zhou F, Euler GL, McPhee SJ, et al. Economic analysis of promotion of hepatitis B vaccination among Vietnamese-American children and adolescents in Houston and Dallas. Pediatrics 2003; 111(6):1289-1296
13. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA 1995;274(15):1201-1208
14. Kessler CS, McGuinn M, Spec A, et al. Underreporting of blood and bodily fluid exposures among health care students and trainees in the acute care setting: a 2007 survey. Am J Infect Control 2011;39:129-134
15. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15(1):1-8
16. Schillie SF, Murphy TV. Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review. Vaccine 2013;31:2506-2516
17. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005;142:333-341
18. McMahon BJ. 30 year follow-up after hepatitis B vaccination in adults and children. In: Viral Hepatitis Prevention Board Meeting; November 2011; Milan.
19. Williams JL, Christensen CJ, McMahon BJ, et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine 2001;19:4081-4085
20. Williams RE. Hepatitis B vaccination coverage among students at a U.S. health science graduate school. In: National Immunization Conference; March 30, 2011; Washington, DC.
21. Maynard J. Passive immunization against hepatitis B: review of recent studies and comment on current aspects of control. Am J Epidemiol 1978;107:77-86
22. McMahon BJ, Schoenberg S, Bulkow L, et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska natives. Am J Epidemiol 1993;138(7):544-549
23. Cruz AC, Frentzen BH, Behnke M. Hepatitis B: a case for prenatal screening of all patients. Am J Ob Gyn 1987:156(5):1180-1183
24. Friedman SM, DeSilva LP, Fox HE, et al. Hepatitis B screening in a New York City obstetrics service. Am J Public Health 1988; 78(3):308-310
25. Kohn MA, Farley TA, Scott C. The need for more aggressive follow-up of children born to hepatitis B surface antigen-positive mothers: lessons from the Louisiana Perinatal Hepatitis Immunization Program. Pediatr Infect Dis J 1996;15(6):535-540
26. Kumar ML, Dawson NV, McCullough AJ, et al. Should all pregnant women be screened for hepatitis B? Ann Intern Med 1987; 107(3):273-277
27. Miriti MK, Billah K, Weinbaum C, et al. Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S. Public Health Rep 2008;123:504-513
28. Centers for Disease Control and Prevention (CDC). CDC Vaccine Price List: Adult Vaccine Price List. Atlanta: CDC, 2011. http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccinemanagement/price-list/index.html. Accessed April 20, 2011
29. Lee JM, Botteman M, Xanthakos N, Nicklasson L. Needlestick injuries in the United States: epidemiologic, economic, and quality of life issues. AAOHN J 2005;53(3):117-133
30. Centers for Disease Control and Prevention (CDC). HBIG Product Information. Atlanta: CDC, 2010. http://www.cdc.gov/hepatitis/PDFs/HBIG_Products&Distributors.pdf. Accessed September 28, 2012
31. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996
32. Lu C-Y, Ni Y-H, Chiang B-L, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008;197:1419-1426
33. Grosse SG. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8(2):165-178
34. Agerton TB, Mahoney FJ, Polish LB, Shapiro CN. Impact of the bloodborne pathogens standard on vaccination of healthcare workers with hepatitis B vaccine. Infect Control Hosp Epidemiol 1995;16:287-291
35. Lu P-J, Euler GL. Influenza, hepatitis B, and tetanus vaccination coverage among health care personnel in the United States. Am J Infect Control 2011;39(6):488-494
36. Reilly M. Evidence for cost-effectiveness analysis: non-cost related model inputs. In: Advisory Committee for Immunization Practices; June 20, 2012; Atlanta.
37. Spradling PR, Xing J, Williams R, et al. Immunity to hepatitis B virus (HBV) infection two decades after implementation of universal infant HBV vaccination: association of detectable residual antibodies and response to a single HBV challenge dose. Clin Vaccine Immunol 2013;20(4):559-561
38. Kim S-Y, Billah K, Lieu TA, Weinstein MC. Cost-effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med 2006;30(6):498-506
39. Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: National Academies Press, 2011.